Expertise in
24
conditions

Dr. Joseph G. Pressey

Hematology | Oncology
Cincinnati Childrens Hospital Medical Center Liberty Campus
7777 Yankee Rd, 
Liberty Township, OH 
Accepting New Patients
Expertise in
24
conditions
Cincinnati Childrens Hospital Medical Center Liberty Campus
7777 Yankee Rd, 
Liberty Township, OH 

Overview

Joseph Pressey is a Hematologist and an Oncologist practicing medicine in Liberty Township, Ohio.

Dr. Pressey is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Malignant Peripheral Nerve Sheath Tumor, Fibrosarcoma, Ewing Sarcoma, and Adult Soft Tissue Sarcoma.

He is actively involved in clinical research, co-authoring 65 peer reviewed articles and participating in 23 clinical trials. Dr. Pressey is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in OH

Hospital Affiliations

Cincinnati Children's Hospital Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
View 3 Less Insurance Carriers -

Locations

Cincinnati Childrens Hospital Medical Center Liberty Campus
7777 Yankee Rd, Liberty Township, OH 45044
Other Locations
Cincinnati Children's Hospital Medical Center
3333 Burnet Ave, Cincinnati, OH 45229

Additional Areas of Focus

Dr. Pressey has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

23 Clinical Trials

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma
Enrollment Status: Suspended
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure
Study Drug: FACT Complex-Targeting Curaxin CBL0137
Study Phase: Phase 1/Phase 2
A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Drug, Biological
Study Drugs: Cytarabine, Flotetuzumab
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: August 20, 2026
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors
A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Nirogacestat
Study Phase: Phase 2
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2026
Intervention Type: Procedure, Drug
Study Drug: Trametinib
Study Phase: Phase 2
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Completed
Publish Date: June 17, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2026
Intervention Type: Drug
Study Drug: Elimusertib
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

65 Total Publications

Retrospective Case Series Highlighting the Real-World Experience of Nirogacestat Therapy in Young Adults With Desmoid Tumors.
Retrospective Case Series Highlighting the Real-World Experience of Nirogacestat Therapy in Young Adults With Desmoid Tumors.
Journal: Pediatric blood & cancer
Published: May 11, 2026
Similar Doctors
Expertise in
22
conditions
Dr. Kasiani C. Myers
Hematology | Oncology
Expertise in
22
conditions
Dr. Kasiani C. Myers
Hematology | Oncology
Referral may be required

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (17.8 miles away)
513-636-4266
Languages Spoken:
English, Greek
See accepted insurances
Accepting New Patients

Kasiani Myers is a Hematologist and an Oncologist practicing medicine in Cincinnati, Ohio. Dr. Myers is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Shwachman-Diamond Syndrome, Congenital Aplastic Anemia, Fanconi Anemia, Aplastic Anemia, and Bone Marrow Transplant. Dr. Myers is currently accepting new patients.

Expertise in
13
conditions
Dr. Russell E. Ware
Hematology | Oncology
Expertise in
13
conditions
Dr. Russell E. Ware
Hematology | Oncology
Referral may be required

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (17.8 miles away)
513-636-4266
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Russell Ware is a Hematologist and an Oncologist practicing medicine in Cincinnati, Ohio. Dr. Ware is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, Anemia, and Splenectomy. Dr. Ware is currently accepting new patients.

Expertise in
15
conditions
Dr. Charles T. Quinn
Hematology | Oncology
Expertise in
15
conditions
Dr. Charles T. Quinn
Hematology | Oncology
Referral may be required

Office

3333 Burnet Ave # 7015, 
Cincinnati, OH 
 (17.8 miles away)
513-636-4266
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Charles Quinn is a Hematologist and an Oncologist practicing medicine in Cincinnati, Ohio. Dr. Quinn is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Hemoglobinopathy. Dr. Quinn is currently accepting new patients.

Frequently Asked Questions about Dr. Joseph G. Pressey

How do I make an appointment with Dr. Joseph G. Pressey?

You can book an appointment with Dr. Joseph G. Pressey by calling their office at 513-636-3200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joseph G. Pressey a top-rated expert for Malignant Peripheral Nerve Sheath Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joseph G. Pressey is classified as an Elite expert for Malignant Peripheral Nerve Sheath Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joseph G. Pressey specialize in?

While Dr. Joseph G. Pressey is a Hematology, they have specific expertise in Malignant Peripheral Nerve Sheath Tumor, Fibrosarcoma, and Ewing Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Joseph G. Pressey participate in research or clinical trials?

Yes. Dr. Joseph G. Pressey has published 65 articles and abstracts on conditions like Malignant Peripheral Nerve Sheath Tumor. You can view a list of Dr. Joseph G. Pressey's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joseph G. Pressey accept my insurance?

Dr. Joseph G. Pressey accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 513-636-3200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pressey's expertise for a condition
ConditionClose
View All 18 Advanced Conditions
View All 71 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile